SCHEMBL30762002

SCHEMBL30762002

[2H]C([2H])([2H])N1CC2(CN(c3nc(C)cc4cnc(NC5CCN(S(=O)(=O)c6cnn(C)c6)CC5)nc34)CC2(F)F)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 19/20 0.48
CCNE1 P24864 13/20 0.48
CCND1 P24385 6/20 0.44
CDK6 Q00534 6/20 0.44
CDK1 P06493 4/20 0.43
CCNB1 P14635 4/20 0.43
CCNT1 O60563 3/20 0.43
CDK4 P11802 3/20 0.43
CDK9 P50750 3/20 0.43
CCND3 P30281 2/20 0.43
CDK7 P50613 1/20 0.43
CCNH P51946 1/20 0.43
MNAT1 P51948 1/20 0.43
CCNB2 O95067 3/20 0.39
CCNE2 O96020 3/20 0.39
CDK5 Q00535 3/20 0.39
CDK5R1 Q15078 3/20 0.39
CCNB3 Q8WWL7 3/20 0.39
CCNA2 P20248 6/20 0.38
CCNK O75909 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27035016 0.95 CDK2 (0.50) CDK2CCNE1CCND1CDK6CDK1
SCHEMBL30761953 0.95 CDK2 (0.50) CDK2CCNE1CCND1CDK6CDK1
SCHEMBL30726209 0.90 CDK2 (0.50) CDK2CCNE1CCND1CDK6CDK1
SCHEMBL27033315 0.90 CDK2 (0.50) CDK2CCNE1CCND1CDK6CDK1
SCHEMBL30761966 0.88 CCNE1 (0.45) CDK2CCNE1CCND1CDK6CDK1
SCHEMBL30761976 0.87 CCNE1 (0.42) CDK2CCNE1CCND1CDK6CDK1
SCHEMBL30761959 0.85 CDK2 (0.48) CDK2CCNE1CCND1CDK6CDK1
SCHEMBL27060673 0.85 CDK2 (0.48) CDK2CCNE1CCND1CDK6CDK1
SCHEMBL30768123 0.85 CDK2 (0.44) CDK2CCNE1CCND1CDK6CDK1
SCHEMBL27034885 0.85 CDK2 (0.44) CDK2CCNE1CCND1CDK6CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250235456-A1 METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS IAMBIC THERAPEUTICS, INC. 2025-07-24 US disclosed
EP-4558502-A1 AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE Iambic Therapeutics, Inc. (US) 2025-05-28 EP disclosed
US-20240034731-A1 AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS, INC. 2024-02-01 US disclosed
WO-2024020419-A1 AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS, INC. (US) 2024-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240034731-A1 AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE CCNI, CDKN1A, CDK8 CDK2 7/4885CCNE1 47/4885CCND1 39/4885
US-20250235456-A1 METHODS OF USE FOR AZA-QUINAZOLINE COMPOUNDS AZI2, TPMT, HDAC10 CDK2 1208/4885CCNE1 423/4885CCND1 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.